Why not prescribe the best drugs for hypertension now? - Wikidata - awgldk - TriplyDB

Why not prescribe the best drugs for hypertension now?

Why not prescribe the best drugs for hypertension now?

http://www.wikidata.org/entity/Q30333019

about

LIFE and SCOPE: what guidance do they offer alongside ALLHAT and ANBP2?

P2860

Q35636620-7AD257FD-5BF6-4970-B169-3610835FED07

P2860

Why not prescribe the best drugs for hypertension now?

http://www.wikidata.org/entity/Q30333019

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Why not prescribe the best drugs for hypertension now?

@ast

Why not prescribe the best drugs for hypertension now?

@en

type

label

Why not prescribe the best drugs for hypertension now?

@ast

Why not prescribe the best drugs for hypertension now?

@en

prefLabel

Why not prescribe the best drugs for hypertension now?

@ast

Why not prescribe the best drugs for hypertension now?

@en

P1433

Q30333019-697408AC-208A-4E50-8B9F-3346848EB83B

P1476

Q30333019-D000B61A-D099-403A-963A-3DB71E0407AC

P2093

Q30333019-6FB47FD3-762A-4BD1-A31B-3B4875B4074A

Q30333019-7A2880A1-5738-49AC-8788-1E852F34319C

Q30333019-F169ED93-51CD-45CC-BF96-E208AC4EAE6E

P2860

Q30333019-042F6AD2-0502-4A28-B8FF-24E38D3AFE44

Q30333019-04675230-0B26-4AF1-8AEE-DA629F0A1D84

Q30333019-0861BD61-CB7A-41CB-B19F-618CBBFDD91B

Q30333019-15041EC5-6FDF-46FB-AB3B-AA484F25E358

Q30333019-22DA20B6-00CC-4C61-9C6B-C74EAE60DB6B

Q30333019-2C0FBDB2-497F-4042-95F5-715E7C5827F9

Q30333019-2E36F539-8C19-46FD-AE2B-AE8EE82999FD

Q30333019-2F952E8E-690C-4A7E-ADF8-D372528C5946

Q30333019-34CF9566-4A6E-4FAE-905E-E80E9AD47A33

Q30333019-3F0AE20C-EEFE-4BB2-A38D-2F851635FAC7

P2888

Q30333019-FED15156-1305-4160-8478-3E003B9C552A

P304

Q30333019-32216428-0688-43C2-9EE2-FD7EFB731F57

P31

Q30333019-9213907B-9D78-4C2A-802F-83089521FB33

P356

Q30333019-A8CBAD67-C7E9-4A4E-95D5-D6A97D2FE3B8

P433

Q30333019-DA454FAD-F619-4533-821E-2137ACB2464E

P478

Q30333019-A78E5154-084D-4A77-815E-897711585FA8

P577

Q30333019-04AB2395-D21B-4285-8499-36CE8FC0A056

P5875

Q30333019-5DF813F6-C7C0-478C-BD64-DD7B083AB909

P6179

Q30333019-90F3343D-36BE-4B09-8B10-7BFC1EC93610

P698

Q30333019-77F70F69-0734-4AB1-91EF-D8257C4E7CEC

P921

Q30333019-25023EFF-7D6C-4EFD-A13C-EF1B579C4156

P356

P1433

Journal of Human Hypertension

P1476

Why not prescribe the best drugs for hypertension now?

@en

P2093

MacDonald TM

http://www.w3.org/2001/XMLSchema#string

McInnes GT

http://www.w3.org/2001/XMLSchema#string

Wong SY

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of Hypertension in the US Adult Population : Results From the Third National Health and Nutrition Examination Survey, 1988-1991

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

Mortality by cause for eight regions of the world: Global Burden of Disease Study

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

P2888

P304

505-511

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.JHH.1001576

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10694834

http://www.w3.org/2001/XMLSchema#string

P6179

1028154720

http://www.w3.org/2001/XMLSchema#string

P698

12821958

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension